|
68 Companies |
|
79 Products |
|
79 Products |
|
71 Mechanisms of Action |
|
0 Trials |
|
484 News |
|
| «12345678910» |
- |||| tradipitant (VLY-686) / Vanda
Enrollment open: Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) - Dec 8, 2013
P2, N=68, Recruiting, Sponsor: Vanda Pharmaceuticals
Not yet recruiting --> Recruiting
- || tacrolimus topical / Generic mfg.
New P3 trial: Tacrolimus Ointment Interest (PROTOPIC (clinicaltrials.gov) - Dec 5, 2013
P3, N=240, Not yet recruiting, Sponsor: University Hospital, Rouen
- ||||| KHK4577 / Kyowa Kirin
New P2 trial: Phase 2 Study of KHK4577 (clinicaltrials.gov) - Dec 4, 2013
P2, N=90, Recruiting, Sponsor: Kyowa Hakko Kirin Company, Limited
- |||| timapiprant (OC000459) / Chiesi
Enrollment open: Effect of OC000459 on Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 4, 2013
P2, N=200, Recruiting, Sponsor: Atopix Therapeutics, Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| tradipitant (VLY-686) / Vanda
New P2 trial: Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) - Dec 4, 2013
P2, N=68, Recruiting, Sponsor: Vanda Pharmaceuticals
- ||||| timapiprant (OC000459) / Chiesi
New P2 trial: Effect of OC000459 on Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Dec 3, 2013
P2, N=200, Recruiting, Sponsor: Atopix Therapeutics, Ltd.
- ||||| Xeljanz (tofacitinib) / Pfizer
Clinical: Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (clinicaltrials.gov) - Dec 2, 2013
P2, N=70, Recruiting, Sponsor: Pfizer
- |||| pegcantratinib (SNA-120) / Sienna
Enrollment open: A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis (clinicaltrials.gov) - Nov 28, 2013
P2, N=210, Recruiting, Sponsor: Creabilis SA
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Clinical: Bleach Bath Treatment of Adults With Atopic Dermatitis (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=40, Not yet recruiting, Sponsor: University of Rochester
- IO biomarker: VIDATOPIC: Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis (clinicaltrials.gov) - Nov 25, 2013
P=N/A, N=100, Not yet recruiting, Sponsor: Pontificia Universidad Catolica de Chile
- |||||||||| fluocinolone acetonide (DF277) / Laboratorios SALVAT
New P3 trial: Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema (clinicaltrials.gov) - Nov 25, 2013
P3, N=135, Completed, Sponsor: Salvat
- Enrollment change: Hydrogel Patch for the Treatment of Eczema (clinicaltrials.gov) - Nov 21, 2013
P=N/A, N=23, Terminated, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting N=30 --> 23
- Clinical: Photocil (Topical) for the Treatment of Atopic Dermatitis (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=50, Recruiting, Sponsor: Applied Biology, Inc.
- Enrollment open: Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=600, Recruiting, Sponsor: Region Skane
N=30 --> 23 Not yet recruiting --> Recruiting
- |||| Dupixent (dupilumab) / Sanofi, Regeneron
Trial completion: Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - Nov 18, 2013
P2, N=109, Completed, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Enrollment open: Phoenix II: Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Nov 14, 2013
P=N/A, N=55, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- pioglitazone / Generic mfg.
Trial withdrawal: Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Rochester
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- pioglitazone / Generic mfg.
Trial initiation date: Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Rochester
Not yet recruiting --> Withdrawn Initiation date: Oct 2012 --> Mar 2013
- pioglitazone / Generic mfg.
Enrollment change: Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients (clinicaltrials.gov) - Nov 7, 2013
P=N/A, N=0, Withdrawn, Sponsor: University of Rochester
Initiation date: Oct 2012 --> Mar 2013 N=38 --> 0
- | Furestem-AD (hUCB-MSCs) / Kangstem Biotech
Enrollment change: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) (clinicaltrials.gov) - Nov 6, 2013
P1/2, N=36, Recruiting, Sponsor: Kang Stem Biotech Co., Ltd.
N=38 --> 0 N=30 --> 36
- | Furestem-AD (hUCB-MSCs) / Kangstem Biotech
Enrollment open: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) (clinicaltrials.gov) - Nov 6, 2013
P1/2, N=36, Recruiting, Sponsor: Kang Stem Biotech Co., Ltd.
N=30 --> 36 Not yet recruiting --> Recruiting
- | ligelizumab (QGE 031) / Novartis
Trial completion: A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients (clinicaltrials.gov) - Oct 20, 2013
P2, N=22, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed
- REGN846 / Regeneron
Trial termination: Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis (clinicaltrials.gov) - Sep 26, 2013
P1/2, N=19, Terminated, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Completed Completed --> Terminated
- ||||| betamethasone/dexchlorpheniramine maleate / Generic mfg., prednisolone / Generic mfg.
Trial initiation date: Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment (clinicaltrials.gov) - Sep 23, 2013
P3, N=140, Not yet recruiting, Sponsor: EMS
Completed --> Terminated Initiation date: Jun 2013 --> Oct 2013
- ||||| Stelara (ustekinumab) / J&J
New P2 trial: A Study of Ustekinumab (STELARA (clinicaltrials.gov) - Sep 16, 2013
P2, N=72, Recruiting, Sponsor: Janssen Pharmaceutical K.K.
- Enrollment open: The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study (clinicaltrials.gov) - Sep 12, 2013
P=N/A, N=80, Recruiting, Sponsor: Ohio State University
Initiation date: Jun 2013 --> Oct 2013 Not yet recruiting --> Recruiting
- | Furestem-AD (hUCB-MSCs) / Kangstem Biotech
New P1/2 trial: Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) (clinicaltrials.gov) - Aug 21, 2013
P1/2, N=36, Recruiting, Sponsor: Kang Stem Biotech Co., Ltd.
- | Trial completion: Management of Pruritus With Xyzal in Atopic Dermatitis (clinicaltrials.gov) - Aug 13, 2013
P4, N=40, Completed, Sponsor: Derm Research, PLLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial withdrawal: Phoenix: Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Aug 8, 2013
P=N/A, N=0, Withdrawn, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: Phoenix: Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis (clinicaltrials.gov) - Aug 8, 2013
P=N/A, N=0, Withdrawn, Sponsor: Bayer
Not yet recruiting --> Withdrawn N=55 --> 0
- ||||| New P4 trial: A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis (clinicaltrials.gov) - Aug 1, 2013
P4, N=120, Recruiting, Sponsor: GlaxoSmithKline
- | New P2 trial: Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis (clinicaltrials.gov) - Jul 16, 2013
P2, N=58, Completed, Sponsor: National Polytechnic Institute, Mexico
- Trial completion: Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis (clinicaltrials.gov) - Jul 15, 2013
P2, N=58, Completed, Sponsor: National Polytechnic Institute, Mexico
N=55 --> 0 Not yet recruiting --> Completed
- | ligelizumab (QGE 031) / Novartis
Enrollment change: A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients (clinicaltrials.gov) - Jul 14, 2013
P2, N=22, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Completed N=30 --> 22
- |||| Eucrisa (crisaborole) / Pfizer
Trial completion: Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis (clinicaltrials.gov) - Jun 20, 2013
P2, N=86, Completed, Sponsor: Anacor Pharmaceuticals, Inc.
N=30 --> 22 Active, not recruiting --> Completed
- ketoconazole / Generic mfg.
Enrollment change: Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo (clinicaltrials.gov) - May 31, 2013
P=N/A, N=32, Completed, Sponsor: St. Louis University
Active, not recruiting --> Completed N=100 --> 32
- ketoconazole / Generic mfg.
Trial completion: Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo (clinicaltrials.gov) - May 31, 2013
P=N/A, N=32, Completed, Sponsor: St. Louis University
N=100 --> 32 Recruiting --> Completed
- Fluzone (influenza vaccine) / Sanofi, Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study (clinicaltrials.gov) - May 22, 2013
P=N/A, N=316, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Dupixent (dupilumab) / Sanofi, Regeneron
Biomarker, New P2 trial: Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov) - May 20, 2013
P2, N=380, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
- Zoryve (roflumilast cream) / Arcutis
New P2 trial: Topical Roflumilast in Adults With Atopic Dermatitis (clinicaltrials.gov) - May 15, 2013
P2, N=40, Recruiting, Sponsor: Takeda Pharma A/S
- | cyclosporine / Generic mfg.
Trial completion: METHODA: Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients (clinicaltrials.gov) - May 12, 2013
P3, N=100, Completed, Sponsor: Hospices Civils de Lyon
Active, not recruiting --> Completed Recruiting --> Completed
- | New P1 trial: Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream (clinicaltrials.gov) - May 8, 2013
P1, N=26, Recruiting, Sponsor: LEO Pharma
- LEO 29102 / LEO Pharma
Trial termination: Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. (clinicaltrials.gov) - Apr 29, 2013
P1, N=58, Terminated, Sponsor: LEO Pharma
Recruiting --> Completed Active, not recruiting --> Terminated
- LEO 29102 / LEO Pharma
Enrollment change: Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. (clinicaltrials.gov) - Apr 29, 2013
P1, N=58, Terminated, Sponsor: LEO Pharma
Active, not recruiting --> Terminated N=74 --> 58
- |||||||||| bepotastine immediate release / Generic mfg.
New P3 trial: A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (clinicaltrials.gov) - Apr 24, 2013
P3, N=303, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Trial completion: A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis (clinicaltrials.gov) - Apr 21, 2013
P4, N=20, Completed, Sponsor: Derm Research, PLLC
N=74 --> 58 Recruiting --> Completed
- REGN846 / Regeneron
Enrollment change: Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis (clinicaltrials.gov) - Apr 17, 2013
P1/2, N=19, Terminated, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Completed N=60 --> 19
- Trial completion: Risk of Asthma in Infants With Atopic Dermatitis (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=120, Completed, Sponsor: Indiana University School of Medicine
N=60 --> 19 Active, not recruiting --> Completed
- ||||| tacrolimus topical / Generic mfg.
New P4 trial: An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis (clinicaltrials.gov) - Apr 9, 2013
P4, N=74, Completed, Sponsor: Janssen-Cilag Ltd.,Thailand
- ||||| New P2 trial: An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis (clinicaltrials.gov) - Apr 4, 2013
P2, N=151, Completed, Sponsor: PreCision Dermatology, Inc.